Head-To-Head Comparison: MeiraGTx (MGTX) & Its Peers

MeiraGTx (NASDAQ:MGTX) is one of 846 public companies in the “Biotechnology” industry, but how does it weigh in compared to its competitors? We will compare MeiraGTx to related companies based on the strength of its earnings, risk, dividends, profitability, analyst recommendations, institutional ownership and valuation.

Volatility & Risk

MeiraGTx has a beta of 1.09, meaning that its share price is 9% more volatile than the S&P 500. Comparatively, MeiraGTx’s competitors have a beta of 1.15, meaning that their average share price is 15% more volatile than the S&P 500.

Profitability

This table compares MeiraGTx and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MeiraGTx	19.87%	283.85%	29.39%
MeiraGTx Competitors	-12,283.59%	-195.39%	-30.85%

Analyst Recommendations

This is a breakdown of current recommendations and price targets for MeiraGTx and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MeiraGTx	0	3	5	0	2.62
MeiraGTx Competitors	9904	15278	45630	1595	2.54

MeiraGTx presently has a consensus target price of $24.00, suggesting a potential upside of 147.93%. As a group, “Biotechnology” companies have a potential upside of 120.42%. Given MeiraGTx’s stronger consensus rating and higher probable upside, analysts clearly believe MeiraGTx is more favorable than its competitors.

Institutional & Insider Ownership

67.5% of MeiraGTx shares are held by institutional investors. Comparatively, 47.7% of shares of all “Biotechnology” companies are held by institutional investors. 7.4% of MeiraGTx shares are held by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares MeiraGTx and its competitors revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
MeiraGTx	$81.39 million	-$114.20 million	13.63
MeiraGTx Competitors	$715.89 million	$12.16 million	-14.86

MeiraGTx’s competitors have higher revenue and earnings than MeiraGTx. MeiraGTx is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Summary

MeiraGTx beats its competitors on 7 of the 13 factors compared.

MeiraGTx Company Profile

MeiraGTx Holdings plc is a biotechnology company developing gene therapies for serious diseases with limited treatment options. Its research focuses on using adeno-associated virus (AAV) vectors to deliver genetic material to target cells, including in programs for inherited retinal diseases, neurological conditions and salivary gland dysfunction. The company also develops manufacturing capabilities and technologies intended to support the production of gene therapies. MeiraGTx was founded in 2015 and has operations in the United States and the United Kingdom.